
Goldman Sachs expects Gland Pharma shares to fall back to their IPO price
Goldman Sachs is anticipating Gland Pharma’s profitability to face headwinds. It has highlighted five factors as to why it believes so.

Goldman Sachs is anticipating Gland Pharma’s profitability to face headwinds. It has highlighted five factors as to why it believes so.

Nuvama Wealth Management Share Price | On Thursday, September 26, CNBC-TV18 reported, citing sources, that Edel Finance Company and Ecap Equities were to sell a…

On Friday, market tech analysts Mitessh Thakkar and Shrikant Chouhan recommended these stocks for the short term.

Indian IT stocks are the top gainers on the Nifty 50 index today, with LTIMindtree leading with a surge of 3%, while Tech Mahindra, Infosys,…

The Nifty 50 is currently trading at 21.5 times its one-year forward earnings whereas the KOSPI commands a valuation of 8.8 times.

Swiggy has a high attrition rate over the last three fiscals as highlighted in its DRHP. Read on to know more about the risk factors.

Post Content

Sensex Today | Stock Market LIVE Updates: Indian benchmark indices Nifty 50 and Sensex ended the previous trade session higher after hitting fresh highs. Nifty…

Equities in Australia advanced, while Japan’s Nikkei index was poised to erase all losses since the Bank of Japan’s July 31 interest rate hike. In…

Traders are waiting for the next batch of catalysts that could give them hints about the economy and the Federal Reserve’s path ahead.